重度新冠后遗症患者心肺运动试验安全性:一项匹配病例对照研究
Safety of cardiopulmonary exercise testing in patients with severe post-COVID-19 condition: a matched case-control study
德国美因茨大学一项匹配病例对照研究纳入18例重度新冠后遗症(PCC)患者与18名按性别、年龄、BMI匹配的健康对照,单次症状限制性心肺运动试验(CPET)后PCC患者症状在1–3天内短暂加重(平均严重度Δ=0.56,p=0.002),4–7天内回落至基线,未达临床意义阈值。
Introduction
Post-COVID-19 condition (PCC) is characterized by long-lasting fatigue, impairments in cognitive and physical functioning, and substantial limitations in daily activities1,2,3. A considerable proportion of PCC patients experience prolonged work disability4,5. However, conventional organ-centered diagnostics often fail to adequately capture the extent of their functional impairments6,7,8. This gap emphasizes the need for a comprehensive and sensitive diagnostic approach to clarify the mechanisms driving persistent symptoms in PCC.
One of the hallmark symptoms in severely affected PCC patients is post-exertional malaise (PEM)9,10. PEM describes a disproportionate and often delayed worsening of symptoms after physical, cognitive, or emotional exertion, typically emerging 24–72 h after the triggering activity and lacking a clear dose-response relationship11,12. Although PEM is a cardinal symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and is frequently reported by severely affected PCC patients, evidence on its severity, temporal dynamics, and physiological correlates remains limited13. A recent literature synthesis by Haunhorst et al. (2025) underscores that physical activity-induced PEM is highly heterogeneous, poorly predictable, and insufficiently characterized14.
Cardiopulmonary exercise testing (CPET) is considered the gold standard for quantifying physical capacity and work ability under controlled conditions15,16,17,18. In PCC and ME/CFS, CPET provides objective measures of exercise capacity and can identify physiological limiting factors19,20; however, concerns about potential symptom deterioration have limited its broader clinical use21,22. Exercise physiology studies in ME/CFS have predominantly employed two-day CPET protocols (with tests separated by 24 h), demonstrating impaired physiological recovery and reproducible reductions in physical capacity on the second test day23,24. Findings from Moore et al., based on a two-day CPET protocol, suggest that recovery abnormalities in ME/CFS extend well beyond cardiopulmonary measures, encompassing prolonged metabolic, autonomic, and symptom-based disturbances following repeated exertion25. However, these two-day protocols conflate the acute PEM response to the first test with the cumulative effect of two closely spaced exertional stressors, making it difficult to isolate the magnitude and time course of PEM following a single exertional event. This distinction is clinically important: before repeated-exercise paradigms can be responsibly applied in severely affected patients, it must first be established whether and to what extent a single maximal, symptom-limited CPET can safely be tolerated. We therefore deliberately selected a single maximal, symptom-limited CPET protocol, which reflects the exposure typical of routine clinical and occupational medicine evaluations of work ability and avoids the additional exertional burden of a second test in a vulnerable population before its safety has been established. Moreover, direct comparisons with healthy matched controls are scarce, making it difficult to isolate PCC- or ME/CFS-specific response patterns.
To address these gaps, the objective of this study is to provide evidence on (i) the physical capacity of PCC patients compared with healthy controls and (ii) the severity and time course of PEM-related symptoms after a single maximal, symptom-limited CPET. We hypothesize that PCC patients will demonstrate reduced physical capacity and a higher baseline symptom burden compared with healthy controls. Furthermore, we expect a single maximal, symptom-limited CPET to transiently intensify PEM-related symptoms in PCC patients. However, it remains uncertain whether this post-exertional response will reach clinically relevant levels or persist beyond the acute post-exercise period.
Methods
Study design
This prospective, matched case-control study was conducted at the Department of Sports Medicine, Prevention and Rehabilitation of the Johannes Gutenberg-University in Mainz, Germany in collaboration with the German Social Accident Insurance for Non-Governmental Health and Social Institutions (German: Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege)26. Ethical approval was granted by the Ethics Committee of the Rhineland-Palatinate Medical Association (Mainz, 06/2024; Reg. No. 2023–17082_2). All procedures adhered to the Declaration of Helsinki, and written informed consent was obtained from all participants. The study protocol consisted of four components: (i) daily baseline tracking of PEM-related symptoms over 7 days; (ii) baseline clinical and functional assessment prior to CPET; (iii) a single maximal, symptom-limited CPET; and (iv) systematic tracking of ten PEM-related symptoms over 14 days after CPET (Fig. 1).
Study design. All participants tracked ten different PEM-related symptoms on a daily basis over a 7-day period, prior to and a 14-day period following the CPET. One day before the CPET, participants completed four cross-sectional questionnaires (Notepad on Day 7). On the day of examination, a baseline clinical assessment was conducted, followed by a single maximal, symptom-limited CPET on a cycle ergometer. PEM: post-exertional malaise; CPET: cardiopulmonary exercise testing.
Except for daily PEM symptom tracking and clinical questionnaires, all assessments were conducted under standardized laboratory conditions and were supervised by physicians and trained clinical exercise physiologists.
Participants
The patients were infected with SARS-CoV-2 at work and have a recognized occupational disease (BK3101) by the German Social Accident Insurance for Non-Governmental Health and Social Institutions. They were unable to work full- or part-time due to PCC and were referred to the Department of Sports Medicine, Prevention and Rehabilitation for comprehensive diagnostic evaluation. Study eligibility was determined according to predefined inclusion and exclusion criteria (Table 1).
Several days to weeks before their routine appointment, patients were contacted by telephone, informed about the study, and provided with written study information materials. After providing written informed consent, they completed a daily questionnaire for seven days prior to their assessment. Upon arrival, all PCC patients were screened for eligibility and formally enrolled in the study. The process of participant inclusion and exclusion is presented as a flowchart in Fig. 2.
Study flowchart. The Study flowchart depicts participant inclusion and exclusion throughout the study. Initially, 20 patients with PCC and 19 matched healthy controls were enrolled. One PCC participant was excluded due to incomplete matching. Of the remaining participants, one PCC participant was excluded because of missing DSQ-PEM data, and one control participant was excluded due to incomplete daily symptom tracking. The final analysis included 36 participants, comprising 18 PCC patients and 18 healthy controls. PCC: post-COVID-19 condition; DSQ-PEM: DePaul Symptom Questionnaire Short-Form for Post-Exertional Malaise.
Healthy controls were recruited through open public advertisements distributed via institutional mailing lists, social media platforms, and local networks. Volunteers expressing interest underwent eligibility screening and were individually matched to PCC patients based on sex, age, and body mass index (BMI) to reduce selection bias and improve covariate balance. We performed exact matching on sex followed by nearest-neighbor matching with calipers on age and BMI. Specifically, each PCC patient was matched to the closest available control participant within the same sex, provided that the difference in age was no more than 5 years and the difference in BMI was no more than 5 kg/m2.
Outcome measures
Patient-reported outcome measures
Prior to the CPET, all participants completed a structured set of patient-reported outcome measures to characterize clinical and functional status. Clinical questionnaires included the Canadian Consensus Criteria (CCC)29 to screen for ME/CFS, and the DePaul Symptom Questionnaire Short-Form-PEM (DSQ-PEM)30 to assess the frequency and severity of PEM-related symptoms and identify patients at risk for PEM. The Bell Disability Scale31 was used to quantify functional capacity on a 0–100 scale.
The objective of the PEM-tracking component was to characterize the time course and severity of post-exertional symptom changes following a single maximal, symptom-limited CPET. Participants completed a digital diary symptom severity score (Supplementary File 1) based on Baraniuk et al.32 in which ten PEM-related symptoms — (i) General exhaustion, (ii) Exertional exhaustion (fatigue triggered by effort), (iii) Muscle pain, (iv) Brain fog, (v) Breathing difficulties (dyspnea), (vi) Sore throat, (vii) Painful lymph nodes, (viii) Joint pain, (ix) Headache, and (x) Sleep disturbances — were rated on a 0–10 Likert scale once daily for seven days prior to CPET and for fourteen days thereafter. Key parameters of interest included: (i) time to peak PEM symptoms, (ii) the magnitude of symptom exacerbation from baseline to peak in comparison to suggested clinically relevant changes on 11-point pain intensity numerical rating scales33, and (iii) the duration required for symptoms to return to baseline levels.
Clinical assessments
All participants underwent comprehensive clinical assessment prior to CPET, which included anthropometric measurements (body mass and body height). A 12-lead resting electrocardiogram (CardioPart 12 PC, AMEDTEC Medizintechnik GmbH, Aue-Bad Schlema, Germany) was performed, along with blood pressure measurement using a digital sphygmomanometer (ERKA, Bad Tölz, Germany). Pulmonary function testing was conducted using body plethysmography (Bodybox 5500, MEDISOFT GmbH, Hamburg, Germany) to measure forced expiratory volume in one second and peak expiratory flow.
Medical history and physical examination were conducted by a study physician following the IPPAF algorithm (inspection, percussion, palpation, auscultation, and functional assessment).
Cardiopulmonary exercise testing
The CPET was conducted on a cycle ergometer (ER 900PC, Ergoline GmBH, Bitz, Germany) and was designed as a single maximal, symptom-limited CPET. The test was designed to last 8–12 min to optimize the assessment of peak oxygen uptake (VO2peak) and peak power output (PPO)15,34. The patients with PCC started exercising at 25 W. Depending on the prior clinical examination, the intensity increased by 10–20 W after every two minutes, until voluntary or symptom-limited (e.g., dizziness, headaches) exhaustion (Fig. 3). Given the heterogeneity of exercise intolerance in PCC patients19 and the vulnerability of this population, we defined a more conservative valid peak effort as achieving a peak respiratory exchange ratio (RER) ≥ 1.0. This approach is consistent with contemporary CPET clinical reporting recommendations in patients with unexplained exertional dyspnea and clinical populations characterized by reduced exercise capacity, including patients with chronic heart failure, chronic obstructive pulmonary disease or interstitial lung diseases35. RER thresholds used to support maximal effort vary widely (e.g., ≥ 1.0, ≥ 1.1, ≥ 1.15), and stricter thresholds can disproportionately exclude patients who reached a high level of physiological exertion but were unable to attain higher RER values due to symptom-limited termination, which can introduce selection bias, especially in older patients36. In addition, large registry data indicate that mean VO2peak values are similar when using RER ≥ 1.0 vs. ≥ 1.1 across sex, ages, and test modes, supporting comparability of VO2peak values while maximizing inclusiveness37.
To ensure the comparability of external load, the healthy controls performed the same protocol with the exact same external load as their matched PCC patients at the beginning, until the point at which the PCC patients reached exhaustion. At this point the controls had a short break of 30–45 s for drawing a venous blood sample. As soon as the vein was successfully punctured, the controls continued the exercise protocol until voluntary exhaustion with individually calculated increments of 20–35 W every two minutes, based on their predicted PPO. We aimed to reach their predicted PPO within the next three stages after the short break. The recovery phase after the termination of the exercise phase was 3 min (1 min resting and 2 min with an external load of 25 W if possible).
Cardiopulmonary exercise testing protocol for the PCC patients and their matched healthy controls. The healthy controls completed the same protocol as their individual matched PCC patients until the patients reached symptom-limited exhaustion. After a short break healthy controls executed a modified protocol until voluntary exhaustion. Red blood drop: venous and capillary blood collection; Stethoscope: blood pressure measurement; Notepad: Rating of subjective perceived exertion. PCC: post-COVID-19 condition; W: workload in watts; min: minutes.
Venous blood samples were drawn 5 min before the CPET and immediately after symptom-limited or voluntary exhaustion. The healthy controls had an additional venous blood drawing right at the timepoint where their matched PCC patient reached symptom-limited exhaustion. Additionally, a small sample of capillary blood (20 µL) was collected from the earlobe at the same timepoints as the venous blood draw, as well as during the final 30 s of each exercise and the recovery phase, to measure blood lactate concentration using the EKF-BIOSEN S-Line system (EKF Diagnostics GmbH, Magdeburg, Germany).
Statistical analysis
All data were processed and analyzed using R (v4.4.3, R Foundation for Statistical Computing, Vienna, Austria) and RStudio (v2026.1.0.392, RStudio, Inc., Boston, USA). All visualizations of the statistical analysis were generated using the ggplot2 package (v4.0.0). Participant matching was conducted using the MatchIt package (v4.7.2).
Categorical variables were reported as absolute counts and percentages and continuous variables were reported as mean ± standard deviation. To assess distributions and homogeneity of variances of continuous variables, Shapiro-Wilk test and Levene’s test were applied, respectively. Depending on the results, we carried out group comparisons using paired t-test (Welch’s t-test) or non-parametric methods (Wilcoxon rank sum test).
To examine the effects of the CPET on the symptom severity over different time periods in PCC patients and healthy controls, we fitted linear mixed-effects models using the lmerTest package (v3.1.3). For the statistical analysis of the symptoms, four observation periods were pre-specified: a baseline period (days − 7 to −1 prior to CPET), an acute period (days 1–3 following CPET), a delayed period (days 4–7 after CPET), and a recovery period (days 8–14 following CPET). The individual and mean symptom severity served as the dependent variables. Group (PCC, Control), time point (baseline, acute, delayed, recovery), and the interaction between group and time point were included as fixed effects. All models included a random effect for participant to account for repeated observations within individuals. After observing significant main effects, pairwise comparisons were obtained with the emmeans package (v2.0.1) using Bonferroni adjustment for multiple testing. The resulting models were evaluated using the performance package (v0.15.3) to generate relevant diagnostic plots and using the DHARMa package (v0.4.7) to create simulation-based residual checks. The statistical significance level was set at p < 0.05.
Results
General characteristics
Baseline characteristics of PCC patients and age-, sex-, and BMI-matched healthy controls are shown in Table 2. By design, age, sex, and BMI were comparable between patients and controls, whereas PCC patients showed significantly higher resting heart rate (HR) compared with controls. Pulmonary function and blood pressure measurements were inconspicuous in both groups with no significant differences.
Cardiopulmonary exercise testing
CPET revealed severe impairments in physical capacity in the patients with PCC, with 68.4% having either a VO2peak below 15 mL/min/kg or a PPO below 1.0 W/kg, which are commonly used thresholds for absolute work disability16,18. Despite the significantly reduced VO2peak, the greatest relative reduction between both cohorts was the difference in PPO (1.1 ± 0.4 vs. 2.3 ± 0.6 W/kg, p < 0.001). The peak HR was significantly lower in the PCC patients compared with the control group (p < 0.001) with higher coefficients of variation (16.3% vs. 9.3%), indicating high inter-individual variability.
The PCC patients showed significantly lower RER values, but only two patients did not reach an RER of 1.0 at exhaustion. However, excluding those two patients did not change any significant difference between patient and control group (Supplementary File 2).
To account for differences in physical capacity between groups, CPET data from matched healthy controls were further analyzed at a submaximal time point defined by the RER at the point at which exercise was terminated for PCC patients, enabling a comparison to be made at a similar level of metabolic stress. Physical capacity defined by VO2peak and PO was still reduced in PCC patients, but HR and blood lactate levels were not significantly different at this timepoint (Table 3).
Patient reported outcome measures
Of the 18 patients with PCC, 11 (61%) were diagnosed with ME/CFS according to the CCC questionnaire, and 12 (67%) fulfilled the PEM criteria as determined by the DSQ-PEM questionnaire. The mean Bell-Score for the PCC patients was 37.8 ± 19.3, ranging from 20 to 90, with 10 patients (56%) having a Bell-Score of 30 or below, indicating a severe limitations in activities of daily living.
Reported PEM-related symptoms and their prevalence, as well as their intensities according to the DSQ-PEM questionnaire, are presented in Fig. 4a. All PCC patients reported having at least sometimes mental fatigue even after minimal effort with mostly moderate-to-severe intensity. Post-activity exhaustion is the second most reported prevalent symptom but with less frequent occurrence.
Results from the DePaul Symptom Questionnaire Short-Form Post-Exertional Malaise. (a) Levels of prevalence (left) and severity (right) of five symptoms, expressed as a percentage of patients. (b) Duration of symptom worsening, expressed as a percentage of patients. Patients showing 14 h or more of symptom worsening are shown in red, while those showing less than 14 h are shown in light blue.
In most PCC patients (58.8%) the worsening of symptoms took 14 h or more, with most patients (35.3%) experiencing a deterioration in their symptoms for more than 24 h (Fig. 4b).
Post-exertional malaise
To compare the course of the different symptoms we calculated the mean symptom severity and summarized this value for different relevant periods (baseline, acute, delayed, recovery), as shown in Fig. 5a. A linear mixed-effects model showed a significant interaction between status and period on mean symptom severity (F(3, 95.0) = 5.74, p = 0.001). Follow-up pairwise comparisons of the different periods were conducted within each cohort using estimated marginal means with Bonferroni adjustment. Within the PCC group, the mean symptom severity was higher during the acute period than during the baseline period (Δ = 0.56, 95% CI [0.15, 0.96], padj = 0.002), representing a relative increase of 16.6%. However, during the delayed period (days 4–7 after CPET) the significant difference to the baseline period disappeared, and the mean symptom severity values during recovery period were significantly lower than during the acute period (Δ = −0.67, 95% CI [−1.08, −0.27], padj < 0.001), even falling below baseline levels. Despite the group mean comparisons, there was much variability between the PCC patients individually (Fig. 5b). No significant differences and less individual variability were observed for the control group.
Mean symptom severity across all PEM-related symptoms for PCC patients and healthy controls over different time periods before and after the CPET (a) and individual symptom severity for each day (b). PEM-related symptoms: (i) General exhaustion, (ii) Exertional exhaustion (fatigue triggered by effort), (iii) Muscle pain, (iv) Brain fog, (v) Breathing difficulties (dyspnea), (vi) Sore throat, (vii) Painful lymph nodes, (viii) Joint pain, (ix) Headache, and (x) Sleep disturbances were rated on a 0–10 Likert scale. Data are presented as estimated means and standard errors, with exact p-values added where post-hoc differences were significant. The statistical significance level was set at p < 0.05. Individual symptom severity is shown as smoothed average using locally estimated scatterplot smoothing (LOESS) and 95% confidence intervals (shaded area). ‘Peak’ defines the highest point of the LOESS curve and ‘Rec’ defines the point at which the LOESS curve reaches baseline levels again. Number of valid data for each day is presented at the bottom of each panel. PCC: Post-COVID-19 condition; CPET: cardiopulmonary exercise testing; PEM: post-exertional malaise.
When analyzing the individual symptoms for the PCC patients, 2/10 symptoms showed significant increases from baseline to the acute period (Supplementary File 4). These two symptoms are general fatigue (Δ = 0.99, 95% CI [0.12, 1.87], padj = 0.018) and joint pain (Δ = 0.69, 95% CI [0.03, 1.35], padj = 0.036), with relative percentage increases of 18.3% and 23.0%, respectively. Similarly to the mean symptom severity, the significant difference to the baseline period disappeared in both symptoms during the delayed period (days 4–7 after CPET).
No significant interactions in the development of acute PEM after CPET were detected when PCC patients were classified into subgroups according to the presence of PEM, as determined by the DSQ-PEM questionnaire (Fig. 6a) or according to their Bell-Scores (Fig. 6b). Additionally, the development of acute PEM after CPET was compared between PCC patients with and without ME/CFS, with no significant interaction (F(3, 45) = 0.76, p = 0.523).
Mean symptom severity across all PEM-related symptoms for PCC patients over different time periods stratified by the DePaul Symptom Questionnaire Short-Form Post-Exertional Malaise (a) and Bell Disability Scale (Bell-Score) (b). PEM-related symptoms: (i) General exhaustion, (ii) Exertional exhaustion (fatigue triggered by effort), (iii) Muscle pain, (iv) Brain fog, (v) Breathing difficulties (dyspnea), (vi) Sore throat, (vii) Painful lymph nodes, (viii) Joint pain, (ix) Headache, and (x) Sleep disturbances were rated on a 0–10 Likert scale. Data are presented as estimated means and standard errors, with exact p-values added where post-hoc differences were significant. The statistical significance level was set at p < 0.05. Individual symptom severity is shown as smoothed average using locally estimated scatterplot smoothing (LOESS) and 95% confidence intervals (shaded area). PCC: Post-COVID-19 condition; CPET: cardiopulmonary exercise testing; PEM: post-exertional malaise; KR: Kenward-Roger approximation.
Discussion
Principal findings
The present study investigated physical capacity and temporal dynamics of PEM-related symptoms following a single maximal, symptom-limited CPET in PCC patients, compared with age-, sex-, and BMI-matched healthy controls. Our findings confirm marked impairments in physical capacity in PCC patients, while demonstrating that a single CPET results in only a transient increase of PEM-related symptoms. These changes did not reach clinically meaningful thresholds and were not associated with sustained symptom deterioration. These findings support the feasibility and safety of a single maximal, symptom-limited CPET in this population and underline its diagnostic utility for individualized clinical decision-making in occupational and rehabilitation settings.
Reduced physical capacity and limiting mechanisms
Consistent with our first hypothesis, PCC patients exhibited markedly reduced physical capacity compared with healthy controls. More than two-thirds of patients met commonly used thresholds for absolute work disability based on VO₂peak (< 15 mL/min/kg) and PPO (< 1.0 W/kg)16,18. These findings are in line with our earlier study, in which we demonstrated in a larger cohort (N = 92) that PCC patients experience pronounced and prolonged impairments in physical capacity38. Notably, the greatest relative difference between groups was observed for PPO (1.1 vs. 2.4 W/kg, p < 0.001) rather than VO₂peak (16.0 vs. 26.5 mL/min/kg; p < 0.001), suggesting that peripheral limitations39,40, reduced ventilatory efficiency41,42, and/or early symptom-driven termination43 may play a important role in exercise intolerance in PCC. This dissociation of a relatively greater reduction in mechanical work output than in oxygen uptake implies an elevated oxygen cost per unit of external load (reduced exercise efficiency) in PCC patients relative to controls. Such a pattern is consistent with impaired skeletal muscle oxidative capacity and mitochondrial dysfunction, which have been reported in PCC and ME/CFS44,45 and would limit the conversion of oxidative metabolism into effective mechanical power even when systemic oxygen delivery is comparatively preserved.
PCC patients achieved significantly lower peak RER than healthy controls (1.07 vs. 1.22, p = 0.001), indicating earlier voluntary termination of exercise. This finding is unlikely to reflect reduced compliance, as perceived exertion at peak exercise was comparable between PCC patients and controls (rate of perceived exertion: 17.8 vs. 18.7, p = 0.2). The dissociation between lower RER and similar perceived exhaustion suggests that PCC patients reach a comparable subjective limit at lower levels of metabolic stress, likely reflecting self-limitation strategies driven by prior experiences with PEM. This pattern is consistent with previous findings in ME/CFS indicating symptom-driven self-limitation and anticipatory pacing behaviors, likely developed to prevent post-exertional symptom exacerbation43. In line with this rationale, we deliberately refrained from strong verbal encouragement or from targeting predefined supramaximal RER thresholds (e.g., > 1.15). Our findings argue against aggressive motivational strategies in this population and support the use of maximal but symptom-limited CPET protocols in both clinical and research settings.
However, self-limitation alone is unlikely to fully explain the observed reduction in physical capacity. Complementary physiological evidence from our previous CPET study suggests that dysfunctional ventilatory regulation and impaired peripheral oxygen utilization substantially contribute to reduced physical capacity in PCC38. In that cohort, 92% of patients exhibited an abnormally elevated ventilatory equivalent for carbon dioxide (VE/VCO₂ slope), accompanied by low resting end-tidal carbon dioxide pressure (PETCO₂) and a blunted PETCO₂ response during exercise, consistent with chronic hyperventilation. Such ventilatory inefficiency increases the metabolic cost of breathing and promotes dyspnea, thereby limiting achievable physical capacity41.
In parallel, oxygen pulse (O₂ pulse)—serving as a non-invasive surrogate of effective oxygen utilization in the absence of overt cardiac pathology46,47—was consistently reduced across exercise intensities and most pronounced in patients fulfilling ME/CFS criteria. Likewise, markedly reduced oxygen uptake efficiency slope (OUES) values indicated inefficient oxygen uptake relative to ventilatory demand35,48. Together, these findings argue against central cardiopulmonary failure as the primary driver of exercise intolerance and instead support a peripheral limitation model39,40, potentially involving microcirculatory or muscular dysfunction. Such impairments would disproportionately affect mechanical efficiency and power generation49, providing a plausible explanation for the larger relative reduction in PPO compared with VO₂peak observed in the present study.
PEM dynamics after a single CPET
In accordance with our second hypothesis, CPET provoked a measurable but modest transient increase in PEM-related symptoms in PCC patients. On a group level, mean symptom severity increased during the acute post-exercise period (Δ = 0.56, p = 0.002) but returned to baseline levels within 4–7 days, with symptom levels during the recovery period falling slightly below baseline. This pattern was not observed in healthy controls, who showed minimal symptom variability throughout the observation period.
At the symptom-specific level, only two of ten PEM-related symptoms—general fatigue (Δ = 0.99, p = 0.018) and joint pain (Δ = 0.69, p = 0.036)—showed statistically significant acute increases, both of which resolved during the delayed period (days 4–7 after CPET). Importantly, no symptoms exhibited persistent worsening beyond the first three days after CPET. These findings indicate that while PCC patients are sensitive to exertional stress, a single maximal, symptom-limited CPET does not induce prolonged or cumulative PEM on a group level. Despite the modest group-level effects, individual symptom trajectories varied substantially among PCC patients. This heterogeneity aligns with previous literature describing PEM as highly individualized, unpredictable, and poorly captured by single time-point assessments11,12,13. However, neither PEM screening status (F(3, 45) = 1.67, p = 0.187) nor functional impairment severity via Bell-Score (F(3, 45) = 1.33, p = 0.276) or ME/CFS status (F(3, 45) = 0.76, p = 0.523) significantly modified acute PEM responses after CPET. This suggests that baseline PEM susceptibility alone may not reliably predict short-term symptom trajectories following standardized exercise, highlighting the importance of individualized monitoring.
Contextualization with existing literature
Given the pronounced intolerance to physical exertion observed in severely affected PCC patients11,12, the potential risk of inducing PEM must be carefully considered when applying CPET. Acute metabolic stress during CPET is associated with lactate accumulation—particularly hydrogen ions50—increased generation of reactive oxygen species51, and transient depletion of cellular energy reserves. In combination with downstream immunometabolic alterations described in PCC and ME/CFS, these processes are considered plausible triggers of PEM and may contribute to delayed or dysregulated recovery14.
Previous investigations of PEM have predominantly employed two-day CPET protocols23,24, which consistently demonstrate impaired recovery and reproducible reductions in physical capacity on the second test day in patients with ME/CFS. Whilst two-day CPET protocols provide valuable mechanistic insights into the pathophysiology of post-exertional symptoms, the time taken to recover to baseline symptom levels is longer (12.7 vs. 4–7 days) and the mean increase in symptom severity is higher (1.5 vs. 0.56 points) compared to our results after a single, symptom-limited CPET. In general, a change of 30% on 11-point pain intensity numerical rating scales represents a minimal clinically important difference33, but neither of the significant symptom increases reached this threshold. From a clinical standpoint, this suggests that a single symptom-limited CPET can be considered a reasonably well-tolerated diagnostic procedure in this population when appropriately supervised and titrated to symptom limitation, rather than a fixed external load target or cut-off values established in healthy individuals. Caution remains warranted in more severely affected individuals who may not tolerate this intensity, or in protocols pushing patients towards supramaximal metabolic stress (RER ≥ 1.15), where more pronounced tissue-level and symptomatic consequences have been observed by Appelman et al.52 Practically, the highly individual insights derived from CPET, including ventilatory and metabolic thresholds, can be used to support medical occupational assessments of work ability and to inform individualized pacing strategies in this population53, while the transient nature of the observed symptom response supports its feasibility as a routine component of such evaluations.
The absence of significant subgroup differences based on DSQ-PEM, Bell-Score, and ME/CFS status may indicate that the acute PEM response to a single symptom-limited CPET is relatively uniform across the PCC spectrum and is not reliably predicted by baseline symptom questionnaires, suggesting that self-reported symptoms or functional impairments at baseline does not necessarily translate into a proportionally greater acute exacerbation following controlled, physical exertion. Taken together, these findings suggest that questionnaire-based screening tools, while valuable for characterizing baseline symptom burden, may have limited utility as standalone gatekeeping criteria for excluding specific PCC phenotypes from a single maximal, symptom-limited CPET a priori, as has been proposed by Gloeckl et al.22 Instead, our findings support an individualized, supervised approach to CPET eligibility, grounded in real-time symptom titration during testing rather than fixed pre-test questionnaire thresholds.
While our data indicate only a transient symptom increase following a single CPET, it is important to recognize that PEM may be triggered not only by acute physical exertion but also by cumulative physical strain (e.g., prolonged travel, lengthy examination days), cognitive demands54, and emotional stress12. Future clinical study designs should therefore consider the potential impact of overall exertional load rather than evaluating isolated procedures in isolation.
Clinical and occupational implications
From an occupational and rehabilitation medicine perspective, our findings have important implications. The absence of sustained PEM exacerbation supports the safe use of maximal, symptom-limited CPET for objective physical capacity evaluation, and individualized rehabilitation planning in PCC and ME/CFS—provided that protocols are carefully designed and patient-centered, without pushing patients beyond their individual limits (e.g., trying to reach RER levels ≥ 1.15).
While recent recommendations caution against maximal CPET in patients with mild to moderate PEM22, they simultaneously advocate structured and carefully dosed physical activity. However, they provide only general objective reference points for intensity control (e.g., 120 bpm), rather than providing individual, objective reference points. In terms of safety in our PCC cohort, the peak HR was 139.7 ± 22.7 bpm (range = 108–185 bpm, coefficient of variation of 16.3%), indicating substantial inter-individual variability in peak HR, likely reflecting heterogeneity in disease severity and in individual mechanisms (e.g., symptom-limitation, dyspnea) limiting physical capacity. Therefore, exercise intensity recommendations based on a HR of 120 bpm would carry a high risk of triggering PEM in some patients, while for others, the intensity might be too low for optimal physiological adaptations.
In this context, the individual load at CPET-derived thresholds (e.g., load and HR at ventilatory or lactate thresholds) offers a crucial framework to guide individualized, symptom-adapted rehabilitation21 while minimizing the risk of PEM exacerbation. Invasive CPET studies39,40 suggest that impaired systemic oxygen extraction becomes increasingly limiting at higher workloads, particularly near or beyond the individual second ventilatory or lactate threshold. Above this metabolic transition, the mismatch between oxygen delivery and utilization may increase anaerobic strain, providing a pathophysiological rationale for metabolism-based PEM threshold management14 Recent real-world data further support shifting exercise prescription and workload management toward the lower end of this metabolic continuum. Ruijgt et al.53 demonstrated delayed autonomic recovery following exercise close to and above the individually determined first ventilatory threshold, with increasing exercise intensity and duration further impairing nighttime heart rate variability (HRV) in patients with PCC. These findings suggest that physical activity, structured exercise and physical work should preferably be performed below—and, depending on individual tolerance, cautiously approaching— first ventilatory threshold, supporting the use of CPET-derived rather than fixed heart-rate limits as an individualized reference for pacing and rehabilitation. Whether structured training or pacing strategies guided by individual metabolic thresholds can be applied safely requires prospective validation. Mean values at the second ventilatory threshold can be found in Supplementary File 3.
Strengths, limitations and future studies
The key strengths of this study include its prospective matched case-control design and daily longitudinal tracking of PEM-related symptoms before and after standardized CPET procedure. Together, these methodological features help to control confounding variables, enhance internal validity, and support reproducibility.
Several limitations should be acknowledged. The noted sample size (n = 18 per group), particularly for subgroup analyses within the PCC cohort, may limit statistical power to detect smaller effect sizes. However, the within-subject design partially mitigates this by eliminating between-subject variability. Nonetheless, the modest sample size increases the risk of type II error for between-group comparisons and limits our ability to explore effect modification by clinical subgroups (e.g., PEM phenotype). Furthermore, the cohort was predominantly female (83%), which may limit the generalizability of our findings to male patients, in whom symptom presentation and physiological responses to exertion may differ. Replication in larger, more sex-balanced cohorts is warranted to confirm the robustness and generalizability of these findings. Another limitation is the reliance on self-reported symptom data without concurrent physiological or molecular measurements of PEM-related mechanisms, such as HRV, inflammatory markers, metabolic alterations, or microstructural muscle changes. Therefore, more research is needed, particularly integrated multimodal approaches—including autonomic nervous system assessment (e.g., HRV), molecular profiling (e.g., proteomics and immunometabolic signatures), muscle biopsies, or advanced imaging—in addition to self-reported symptoms before and after CPET protocols. Such approaches may further elucidate the pathophysiological links between subjective symptom exacerbation and underlying cellular or systemic responses.
Conclusion
PCC patients exhibit marked impairment in physical capacity and a high baseline symptom burden compared with matched healthy controls. A single maximal, symptom-limited CPET was associated with a transient, but not clinically relevant, increase in PEM-related symptoms during the first 1–3 days, without evidence of prolonged exacerbation or sustained clinical deterioration. These findings support the use of symptom-limited CPET to objectively quantify exercise intolerance and to derive individualized threshold values that may help guide activity management and minimize persistent PEM during rehabilitation, work and daily life.
Data availability
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
Code availability
The code generated during the current study is available from the corresponding author on reasonable request.
Abbreviations
- BMI:
-
Body mass index
- BPdia :
-
Diastolic blood pressure
- BPsys :
-
Systolic blood pressure
- CCC:
-
Canadian consensus criteria
- CPET:
-
Cardiopulmonary exercise testing
- DSQ-PEM:
-
DePaul symptom questionnaire short-form-PEM
- HR:
-
Heart rate
- HRV:
-
Heart rate variability
- ME/CFS:
-
Myalgic encephalomyelitis/chronic fatigue syndrome
- PCC:
-
Post-COVID-19 condition
- PEM:
-
Post-exertional malaise
- PETCO2 :
-
End-tidal carbon dioxide pressure
- PO:
-
Power output
- PPO:
-
Peak power output
- RER:
-
Respiratory exchange ratio
- RPE:
-
Rate of perceived exertion
- SARS‑CoV‑2:
-
Severe acute respiratory syndrome coronavirus 2
- VO2 :
-
Oxygen uptake
- VO2peak :
-
Peak oxygen uptake
References
Parotto, M. et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med.11, 739–754. https://doi.org/10.1016/S2213-2600(23)00239-4 (2023).
O’Mahoney, L. L. et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine55, 101762. https://doi.org/10.1016/j.eclinm.2022.101762 (2023).
O’ Mahony, L. et al. Impact of Long COVID on health and quality of life. HRB Open. Res.5, 31. https://doi.org/10.12688/hrbopenres.13516.1 (2022).
Ottiger, M., Poppele, I., Sperling, N., Schlesinger, T. & Müller, K. Work ability and return-to-work of patients with post-COVID-19: a systematic review and meta-analysis. BMC Public. Health. 24, 1811. https://doi.org/10.1186/s12889-024-19328-6 (2024).
Daniell, J. et al. and. The rising cost of Long COVID and ME/CFS in Germany. (2025). https://mecfs-research.org/wp-content/uploads/2025/05/The-rising-cost-of-Long-COVID-and-MECFS-in-Germany.pdf. Accessed May 2025.
Goertzen, S. M. et al. Clinical, Radiographic, and Physiological Correlates of Post-COVID-19 Dyspnea in Military Health System Beneficiaries: Results From the Chronic Impairment With Pulmonary Symptoms (ChIPS) Sub-study. Open. Forum Infect. Dis.12, ofaf633. https://doi.org/10.1093/ofid/ofaf633 (2025).
Furevik, L. L. et al. Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study. Front. Neurol.16, 1662263. https://doi.org/10.3389/fneur.2025.1662263 (2025).
Lingering cardiac involvement in previously well people after mild COVID-19. Nat. Med. ;28:2011–2012. doi:https://doi.org/10.1038/s41591-022-02002-y. (2022).
Tokumasu, K. et al. Clinical Characteristics of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Diagnosed in Patients with Long COVID. Med. (Kaunas). https://doi.org/10.3390/medicina58070850 (2022).
AlMuhaissen, S. et al. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and COVID-19: is there a connection? Curr. Med. Res. Opin.39, 1119–1126. https://doi.org/10.1080/03007995.2023.2242244 (2023).
Holtzman, C. S., Bhatia, S., Cotler, J. & Jason, L. A. Assessment of Post-Exertional Malaise (PEM) in Patients with Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS): A Patient-Driven Survey. Diagnostics (Basel). https://doi.org/10.3390/diagnostics9010026 (2019).
Hartle, M., Bateman, L. & Vernon, S. D. Dissecting the nature of post-exertional malaise. Fatigue: Biomed. Health Behav.9, 33–44. https://doi.org/10.1080/21641846.2021.1905415 (2021).
Vøllestad, N. K. & Mengshoel, A. M. Post-exertional malaise in daily life and experimental exercise models in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front. Physiol.14, 1257557. https://doi.org/10.3389/fphys.2023.1257557 (2023).
Haunhorst, S. et al. Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome. Infectionhttps://doi.org/10.1007/s15010-024-02386-8 (2024).
Kroidl, R. F., Schwarz, S., Lehnigk, B. & Fritsch, J. Kursbuch Spiroergometrie: Technik und Befundung verständlich gemacht 3rd edn. (Thieme, 2015).
Preisser, A. M. & Ochmann, U. Die Spiroergometrie in der arbeitsmedizinischen Eignungsuntersuchung und Begutachtung. [Cardiopulmonary exercise testing in occupational medical fitness examination and assessment]. Pneumologie65, 662–670. https://doi.org/10.1055/s-0031-1291463 (2011).
Funk, M. & Schneider, J. Spiroergometrische Referenzwerte für die sozialmedizinische Leistungsbeurteilung bei Erwachsenen im Alter über 60 Jahre. [Spiroergometric reference values for the sociomedical assessment of performance in adults aged over 60 years]. Pneumologie66, 329–337. https://doi.org/10.1055/s-0032-1309362 (2012).
American Thoracic Society. Evaluation of impairment/disability secondary to respiratory disorders. Am. Rev. Respir Dis.133, 1205–1209. https://doi.org/10.1164/arrd.1986.133.6.1205 (1986).
Durstenfeld, M. S. et al. Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults: A Systematic Review and Meta-analysis. JAMA Netw. open.5, e2236057. https://doi.org/10.1001/jamanetworkopen.2022.36057 (2022).
Joseph, P. et al. Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of SARS-CoV-2: More in Common Than Not? Chest164, 717–726. https://doi.org/10.1016/j.chest.2023.03.049 (2023).
Singh, S. J. et al. Balancing the value and risk of exercise-based therapy post-COVID-19: a narrative review. Eur. respiratory review: official J. Eur. Respiratory Soc.https://doi.org/10.1183/16000617.0110-2023 (2023).
Gloeckl, R. et al. Practical Recommendations for Exercise Training in Patients with Long COVID with or without Post-exertional Malaise: A Best Practice Proposal. Sports Med. Open.10, 47. https://doi.org/10.1186/s40798-024-00695-8 (2024).
Lim, E-J., Kang, E-B., Jang, E-S. & Son, C-G. The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis. J. Clin. Med.https://doi.org/10.3390/jcm9124040 (2020).
Keller, B. et al. Cardiopulmonary and metabolic responses during a 2-day CPET in myalgic encephalomyelitis/chronic fatigue syndrome: translating reduced oxygen consumption to impairment status to treatment considerations. J. Transl Med.22, 627. https://doi.org/10.1186/s12967-024-05410-5 (2024).
Moore, G. E. et al. Recovery from Exercise in Persons with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Med. (Kaunas). https://doi.org/10.3390/medicina59030571 (2023).
Tomaskovic, A. et al. Multimodal Web-Based Telerehabilitation for Patients With Post-COVID-19 Condition: Protocol for a Randomized Controlled Trial. JMIR Res. Protoc.14, e65044. https://doi.org/10.2196/65044 (2025).
Casser, H-R., Seddigh, S. & Rauschmann, M. Acute Lumbar Back Pain. Dtsch. Arztebl Int.113, 223–234. https://doi.org/10.3238/arztebl.2016.0223 (2016).
Blumberg, H. M. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir Crit. Care Med.167, 603–662. https://doi.org/10.1164/rccm.167.4.603 (2003).
Carruthers, B. M. et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndrome. 11, 7–115. https://doi.org/10.1300/J092v11n01_02 (2003).
Cotler, J., Holtzman, C., Dudun, C. & Jason, L. A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics8, 66. https://doi.org/10.3390/diagnostics8030066 (2018).
Bell, D. S. The doctor’s guide to chronic fatigue syndrome (Perseus Books, 1995).
Baraniuk, J. N. et al. A Chronic Fatigue Syndrome (CFS) severity score based on case designation criteria. Am. J. Transl Res.5, 53–68 (2013).
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L. & Poole, M. R. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain94, 149–158. https://doi.org/10.1016/S0304-3959(01)00349-9 (2001).
Löllgen, H. & Leyk, D. Exercise Testing in Sports Medicine. Dtsch. Arztebl Int.115, 409–416. https://doi.org/10.3238/arztebl.2018.0409 (2018).
Guazzi, M. et al. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur. Heart J.39, 1144–1161. https://doi.org/10.1093/eurheartj/ehw180 (2018).
Edvardsen, E., Hem, E. & Anderssen, S. A. End criteria for reaching maximal oxygen uptake must be strict and adjusted to sex and age: a cross-sectional study. PLoS One. 9, e85276. https://doi.org/10.1371/journal.pone.0085276 (2014).
Kaminsky, L. A. et al. Updated Reference Standards for Cardiorespiratory Fitness Measured with Cardiopulmonary Exercise Testing: Data from the Fitness Registry and the Importance of Exercise National Database (FRIEND). Mayo Clin. Proc.97, 285–293. https://doi.org/10.1016/j.mayocp.2021.08.020 (2022).
Tomaskovic, A. et al. Cardiopulmonary Exercise Testing Reveals Functional Limitations and Work Disability in Severe Post-COVID-19 and ME/CFS Patients. Sports Med. Open.https://doi.org/10.1186/s40798-026-00995-1 (2026).
Singh, I. et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest161, 54–63. https://doi.org/10.1016/j.chest.2021.08.010 (2022).
Leitner, B. P. et al. The metabolic and physiologic impairments underlying long COVID associated exercise intolerance. Pulm Circ.14, e70009. https://doi.org/10.1002/pul2.70009 (2024).
Wirth, K. J. & Scheibenbogen, C. Dyspnea in Post-COVID Syndrome following Mild Acute COVID-19 Infections: Potential Causes and Consequences for a Therapeutic Approach. Med. (Kaunas). https://doi.org/10.3390/medicina58030419 (2022).
Taverne, J. et al. High incidence of hyperventilation syndrome after COVID-19. J. Thorac. Dis.13, 3918–3922. https://doi.org/10.21037/jtd-20-2753 (2021).
Nijs, J. et al. Fear of movement and avoidance behaviour toward physical activity in chronic-fatigue syndrome and fibromyalgia: state of the art and implications for clinical practice. Clin. Rheumatol.32, 1121–1129. https://doi.org/10.1007/s10067-013-2277-4 (2013).
Schäfer, H., Teschler, M., Mooren, F. C. & Schmitz, B. Altered tissue oxygenation in patients with post COVID-19 syndrome. Microvasc Res.148, 104551. https://doi.org/10.1016/j.mvr.2023.104551 (2023).
Baratto, C. et al. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. J. Appl. Physiol. (Bethesda Md. : 1985). 130, 1470–1478. https://doi.org/10.1152/japplphysiol.00710.2020 (2021).
Mezzani, A. Cardiopulmonary Exercise Testing: Basics of Methodology and Measurements. Ann. Am. Thorac. Soc.14, S3–S11. https://doi.org/10.1513/AnnalsATS.201612-997FR (2017).
Balady, G. J. et al. Clinician’s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation122, 191–225. https://doi.org/10.1161/CIR.0b013e3181e52e69 (2010).
Baba, R. et al. Oxygen intake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relationship between oxygen consumption and minute ventilation during incremental exercise. Nagoya J. Med. Sci.59, 55–62 (1996).
Schwendinger, F., Knaier, R., Radtke, T. & Schmidt-Trucksäss, A. Low Cardiorespiratory Fitness Post-COVID-19: A Narrative Review. Sports Med.53, 51–74. https://doi.org/10.1007/s40279-022-01751-7 (2023).
Wan, J-J., Qin, Z., Wang, P-Y., Sun, Y. & Liu, X. Muscle fatigue: general understanding and treatment. Exp. Mol. Med.49, e384. https://doi.org/10.1038/emm.2017.194 (2017).
He, F. et al. Redox Mechanism of Reactive Oxygen Species in Exercise. Front. Physiol.7, 486. https://doi.org/10.3389/fphys.2016.00486 (2016).
Appelman, B. et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat. Commun.15, 17. https://doi.org/10.1038/s41467-023-44432-3 (2024).
Ruijgt, T. M., Slaghekke, A., Ellens, A., Janssen, K. W. & Wüst, R. C. I. Wearable Heart Rate Variability Monitoring, Autonomic Dysfunction and Post-exertional Malaise in Long COVID: An Observational Study. Sports Med.https://doi.org/10.1007/s40279-026-02487-4 (2026).
Dominique de Quervain. Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment (FamC) 2024-07-18.
Acknowledgements
The authors would like to thank the participants who have been included for giving their time, energy, and experience, which the authors hope will further improve scientific knowledge and healthcare for all patients with post-COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome. We acknowledge that ChatGPT-5 (OpenAI, San Francisco, CA, USA) was used to improve the manuscript’s wording and readability. The tool was used solely for language refinement, not for text generation.
Funding
This study is a collaborative project between the Department of Sports Medicine, Prevention and Rehabilitation, Institute of Sport Science, Johannes Gutenberg-University Mainz (Germany) and the German Social Accident Insurance for Non-Governmental Health and Social Care Institutions (German: Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege; BGW). The study receives funding from the BGW. This sponsor was not involved in the study design, the writing of the manuscript, or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Department of Sports Medicine, Prevention and Rehabilitation, Institute for Sport Science, Johannes Gutenberg-University Mainz, Mainz, Germany
Vincent Weber, Aleksandar Tomaskovic, David T. Ochmann, Barlo Hillen, Severin Zentgraf, Mirjam S. Enger, Ella Lachtermann, Elmo W. I. Neuberger & Perikles Simon
Institute for Occupational, Social and Environmental Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
Barlo Hillen
Authors
- Vincent Weber
- Aleksandar Tomaskovic
- David T. Ochmann
- Barlo Hillen
- Severin Zentgraf
- Mirjam S. Enger
- Ella Lachtermann
- Elmo W. I. Neuberger
- Perikles Simon
Contributions
Conceptualization, P.S., A.T., V.W., B.H., E.W.I.N.; Data collection, D.T.O., E.L., S.Z., E.W.I.N.; Data curation, V.W.; Data interpretation, V.W. and A.T.; Visualization, V.W.; Writing – original draft preparation, V.W. and A.T.; Writing – Review & Editing, V.W., A.T., B.H., E.W.I.N., D.T.O., S.Z., M.S.E., E.L., and P.S.; Supervision, P.S. All authors have read and agreed to the final version of the manuscript.
Corresponding author
Correspondence to Perikles Simon.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
All procedures were approved by the Ethics Committee of the Rhineland-Palatinate Medical Association (Mainz, 06/2024; Reg Num: 2023–17082_2).
Consent to participate
All study participants provided both verbal and written consent, after being informed of the experimental procedures, which conform to the guidance presented in the Declaration of Helsinki.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Weber, V., Tomaskovic, A., Ochmann, D.T. et al. Safety of cardiopulmonary exercise testing in patients with severe post-COVID-19 condition: a matched case-control study. Sci Rep 16, 31123 (2026). https://doi.org/10.1038/s41598-026-72075-z
Received: 04 May 2026
Accepted: 15 September 2026
Published: 06 October 2026
Version of record: 06 October 2026
DOI: https://doi.org/10.1038/s41598-026-72075-z
Keywords
来源:Nature 健康护理主题 · nature.com